Mohit Rawat
President bij FUSN PHAR
Vermogen: 273 813 $ op 31-03-2024
Oorsprong van het eerstegraads netwerk van Mohit Rawat
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
22
| Public Company | Pharmaceuticals: Major | 22 |
10
| Public Company | Pharmaceuticals: Major | 10 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Mohit Rawat via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| ABBOTT LABORATORIES | Medical Specialties | Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| GILEAD SCIENCES, INC. | Biotechnology | Corporate Officer/Principal | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
Allos Therapeutics, Inc.
 Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
| IDENIX PHARMACEUTICALS INC | Pharmaceuticals: Major | Investor Relations Contact Corporate Officer/Principal | |
Novartis International AG
 Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. | Pharmaceuticals: Major | Corporate Officer/Principal | |
| AEGERION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Investor Relations Contact | |
| IPSEN | Pharmaceuticals: Major | Chief Executive Officer | |
| INTERCEPT PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Director/Board Member | |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers. | Miscellaneous Commercial Services | Director/Board Member Director/Board Member | |
| SUTRO BIOPHARMA, INC. | Pharmaceuticals: Major | Corporate Officer/Principal | |
Aptalis Pharma LLC
 Aptalis Pharma LLC Pharmaceuticals: MajorHealth Technology Aptalis Pharma, Inc. develops, manufactures, markets pharmaceutical products for cystic fibrosis and gastroenterology. The company's products include Zenpep, Canasa, Carafate, Pylera, Lacteal, Panzytrat, Delursan, Rectiv and Salofalk.. It provides therapies for unmet medical needs including cystic fibrosis and gastrointestinal disorders. The company formulates and clinically develops enhanced pharmaceutical and biopharmaceutical products for itself and others using its proprietary pharmaceutical technology. Aptalis Pharma was founded 1982 and is headquartered in Birmingham, AL. | Pharmaceuticals: Major | Director/Board Member Director of Finance/CFO | |
| BAXALTA INC | Biotechnology | Corporate Officer/Principal | |
| Stanford University | College/University | Undergraduate Degree | |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal | |
| Drexel University | College/University | Undergraduate Degree | |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| McGill University | College/University | Doctorate Degree Doctorate Degree | |
| MIRATI THERAPEUTICS | Biotechnology | Chief Executive Officer | |
| Boston College | College/University | Undergraduate Degree | |
| Yale University | College/University | Graduate Degree Doctorate Degree | |
| McMaster University | College/University | Corporate Officer/Principal Undergraduate Degree | |
| University of Cincinnati (Ohio) | College/University | Undergraduate Degree | |
| The University of Colorado | College/University | Corporate Officer/Principal Doctorate Degree | |
| ENDOCYTE, INC. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Corporate Officer/Principal | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Director/Board Member | |
European Federation of Pharmaceutical Industries & Assns
 European Federation of Pharmaceutical Industries & Assns Miscellaneous Commercial ServicesCommercial Services The European Federation of Pharmaceutical Industries & Assns is a trade association that promotes pharmaceutical discovery and development. The non-profit company is based in Brussels, Belgium. | Miscellaneous Commercial Services | Director/Board Member | |
Novartis Pharmaceuticals Canada, Inc.
 Novartis Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Novartis Pharmaceuticals Canada, Inc. manufactures chemicals and pharmaceuticals products. It provides solutions on patients suffering from a variety of major illnesses including cancer, cardiovascular diseases, Alzheimer's disease, age-related macular degeneration, organ transplantation, and osteoporosis. The company was founded in 1996 and is headquartered in Dorval, Canada. | Pharmaceuticals: Major | Chief Executive Officer | |
| OTONOMY | Biotechnology | Director/Board Member Director/Board Member | |
Ipsen Pharma SAS
 Ipsen Pharma SAS Pharmaceuticals: MajorHealth Technology Ipsen Pharma SAS is a biopharmaceutical company that develops medicines in oncology, neuroscience and rare diseases. The company was founded by Henri Beaufour in 1929 and is headquartered in Boulogne-Billancourt, France. | Pharmaceuticals: Major | Chairman | |
| ADVANCED ACCELERATOR APPLICATION SA(ADR) | Medical Specialties | Director/Board Member | |
Ipsen Manufacturing Ireland Ltd.
 Ipsen Manufacturing Ireland Ltd. BiotechnologyHealth Technology Ipsen Manufacturing Ireland Ltd. operates as a biopharmaceutical group dedicated to improving lives through innovative medicines. The company was founded in 1989 and is headquartered in Dublin, Ireland. | Biotechnology | Chief Executive Officer | |
Sharon Merrill Associates, Inc.
 Sharon Merrill Associates, Inc. Miscellaneous Commercial ServicesCommercial Services Sharon Merrill Associates, Inc. is a full-service investor relations and corporate communications strategic advisory agency. Sharon Merrill Associates is based in Boston, MA. The private company has an international reputation as a preeminent strategic IR advisory firm. Sharon Merrill partners with IROs and the C-suite to drive value for both external and internal stakeholders. Clients have relied on their senior-level counsel and communications expertise for more than 35 years to guide them through every challenge and meet every opportunity. The company takes a strategic approach to every situation as they leverage sophisticated stakeholder engagement and innovative digital media, social media, and branding strategies to help clients build enduring and value-creating relationships with the right audiences. Maureen T. Wolff has been the CEO of the company since 1985. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
| Harron & Associates, Inc. | Corporate Officer/Principal | ||
| UNIQURE N.V. | Biotechnology | Chairman | |
| Harvard Law School | College/University | Graduate Degree | |
| MIT Sloan School of Management | College/University | Masters Business Admin | |
| INTELLIA THERAPEUTICS, INC. | Biotechnology | Director/Board Member Chief Executive Officer Chief Operating Officer | |
Entasis Therapeutics, Inc.
 Entasis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Entasis Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovey, development, and commercialization of novel antibacterial prodcuts to treat serious infections caused by multi-drug resistant Gram-negative bacteria. Its pipeline includes ETX2514SUL, targeting Acinetobacter baumannii infections; ETX0282CPDP, targeting Enterobacteriaceae infections; a Non-Beta-lactam PBP inhibitor, targeting Gram-negative infections; and zoliflodacin, targeting Neisseria gonorrhoeae. The company was founded by Manoussos Perros in May 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member Chairman | |
| MEREO BIOPHARMA GROUP PLC | Biotechnology | Director/Board Member | |
Tizona Therapeutics, Inc.
 Tizona Therapeutics, Inc. BiotechnologyHealth Technology Tizona Therapeutics, Inc. is an immunology company harnessing the power of the immune system to develop treatments for cancer and autoimmune diseases. Its products include anti-ccr4 antibody for the treatment of cancer, il-35 antagonists for the treatment of cancer, and il-35 agonists for the treatment of autoimmune diseases. The company was founded by Charles G. Drake, Vijay K. Kuchroo, Drew M. Pardoll, Dario Vignali, Wayne A. Marasco and Jedd D. Wolchok and is headquartered in South San Francisco, CA. | Biotechnology | Chief Executive Officer Chief Operating Officer | |
Centre For Probe Development & Commercialization
 Centre For Probe Development & Commercialization Pharmaceuticals: MajorHealth Technology Centre for Probe Development & Commercialization (CPDC) is a leader in the discovery, development, and commercialization of next-generation radiopharmaceuticals. The private company is based in Hamilton, Canada, and was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University, and the Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a renowned, robust, and reliable platform for the manufacturing and supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. The Canadian company was founded in 2008 by John Valliant, and the CEO is Bruno Paquin. | Pharmaceuticals: Major | Chief Tech/Sci/R&D Officer Founder | |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
| ENTASIS THERAPEUTICS HOLDINGS INC. | Biotechnology | Director/Board Member Chairman | |
FerGene, Inc.
 FerGene, Inc. BiotechnologyHealth Technology FerGene, Inc. provides gene therapy solutions to urologists. The company is headquartered in Cambridge, MA. | Biotechnology | Chief Executive Officer | |
DOT Therapeutics-2, Inc.
 DOT Therapeutics-2, Inc. Pharmaceuticals: MajorHealth Technology DOT Therapeutics-2, Inc. develops new therapies that change the outcome for people of all ages living with cancer. The company was founded by Julie Grant and Samuel Blackman and is headquartered in South San Francisco, CA. | Pharmaceuticals: Major | Chief Executive Officer | |
| DAY ONE BIOPHARMACEUTICALS, INC. | Pharmaceuticals: Major | Chief Executive Officer | |
| Camping & Education Foundation | Director/Board Member |
Statistieken
Internationaal
| Verenigde Staten | 37 |
| Canada | 6 |
| Frankrijk | 4 |
| Zwitserland | 2 |
| Japan | 2 |
Sectoraal
| Health Technology | 35 |
| Consumer Services | 11 |
| Commercial Services | 5 |
Operationeel
| Director/Board Member | 161 |
| Corporate Officer/Principal | 75 |
| Independent Dir/Board Member | 53 |
| Undergraduate Degree | 28 |
| Chief Tech/Sci/R&D Officer | 20 |
Sterkste connecties
| Insiders | |
|---|---|
| Chau Khuong | 38 |
| Johan Rutger Christenson | 35 |
| Heather Elizabeth Preston | 34 |
| Pablo Cagnoni | 24 |
| Barbara Duncan | 22 |
| David Meek | 18 |
| John Leonard | 17 |
| Steven Gannon | 14 |
| Jeremy Bender | 12 |
| Gary Winer | 10 |
| Lars Kielhorn | 9 |
| Paul Wierbicki | 9 |
| Donald Frail | 9 |
| Donald Bergstrom | 9 |
| John Crowley | 9 |
- Beurs
- Insiders
- Mohit Rawat
- Bedrijfsconnecties
